Madrigal Pharmaceuticals, Inc. (LON:0JXI)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 8.39B +83.3% |
| Revenue (ttm) | 857.64M +256.8% |
| Net Income | -234.34M |
| EPS | -10.34 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7 |
| Open | 495.27 |
| Previous Close | 477.46 |
| Day's Range | 486.00 - 497.42 |
| 52-Week Range | 275.13 - 610.61 |
| Beta | -1.05 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 4, 2026 |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. [Read more]
Financial Performance
In 2025, Madrigal Pharmaceuticals's revenue was $958.40 million, an increase of 432.05% compared to the previous year's $180.13 million. Losses were -$288.28 million, -38.12% less than in 2024.
Financial numbers in USD Financial StatementsNews
Madrigal Pharmaceuticals announces new analyses of Rezdiffra data
Madrigal Pharmaceuticals (MDGL) announced new analyses of Phase 3 data and real-world evidence demonstrating Rezdiffra reduced markers of cardiovascular and liver-related risk in patients with MASH. T...
Madrigal Pharmaceuticals price target raised to $709 from $640 at Truist
Truist raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $709 from $640 and keeps a Buy rating on the shares. The firm’s survey work reinforces its belief in…
Madrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord
Canaccord lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $578 from $587 and keeps a Buy rating on the shares. The firm updated its model following Q1 results…
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
Evercore ISI lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $649 from $652 and keeps an Outperform rating on the shares.
Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)
Reports Q1 revenue $311.34M, consensus $300.92M. Bill Sibold, Chief Executive Officer of Madrigal, stated: “2026 is off to a terrific start. Rezdiffra has achieved blockbuster status on a trailing-12-...
Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street
Clear Street raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $680 from $533 and keeps a Buy rating on the shares post the Q1 report. The firm says…
Madrigal Pharmaceuticals Earnings Call Transcript: Q1 2026
Rezdiffra posted $311M in Q1 2026 net sales, up 127% year-over-year, with over 42,250 active patients and strong market expansion. The company is investing in a broad pipeline and expects robust growth, though profitability is not anticipated in 2026.
Madrigal Pharmaceuticals Earnings release: Q1 2026
Madrigal Pharmaceuticals released its Q1 2026 earnings on May 6, 2026, summarizing the period's financial results.
Madrigal Pharmaceuticals Slides: Q1 2026
Madrigal Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 6, 2026.
Madrigal Pharmaceuticals Quarterly report: Q1 2026
Madrigal Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 6, 2026.
Arrowhead announces exclusive worldwide license agreement with Madrigal Pharma
Arrowhead Pharmaceuticals (ARWR) announced an exclusive worldwide license agreement with Madrigal Pharmaceuticals (MDGL) for ARO-PNPLA3, Arrowhead’s clinical stage RNA interference therapeutic designe...
Madrigal Pharmaceuticals Proxy statement: Proxy filing
Madrigal Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Madrigal Pharmaceuticals Proxy statement: Proxy filing
Madrigal Pharmaceuticals filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Madrigal Pharmaceuticals off highs, remains up 13% in afternoon trading
14:57 EDT Madrigal Pharmaceuticals (MDGL) off highs, remains up 13% in afternoon trading
Madrigal Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference
Rezdiffra is driving strong revenue growth, with 2025 sales projected near $1 billion and a robust pipeline expansion. Market penetration remains low, offering significant upside, while international growth and new combination therapies are set to accelerate from 2027 onward.
Madrigal Pharmaceuticals price target lowered to $529 from $570 at BofA
BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $529 from $570 and keeps a Neutral rating on the shares. Following quarterly results and the associated call, the…
Madrigal Pharmaceuticals Earnings Call Transcript: Q4 2025
Rezdiffra achieved nearly $1B in first-year net sales, driving robust growth in a rapidly expanding US MASH market. The company expects continued strong performance in 2026, supported by a deep pipeline, broad payer access, and a strong cash position.
Madrigal Pharmaceuticals Annual report: Q4 2025
Madrigal Pharmaceuticals has published its Q4 2025 annual report on February 19, 2026.
Madrigal Pharmaceuticals Earnings release: Q4 2025
Madrigal Pharmaceuticals released its Q4 2025 earnings on February 19, 2026, summarizing the period's financial results.
Madrigal Pharmaceuticals Slides: Q4 2025
Madrigal Pharmaceuticals has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on February 19, 2026.
Madrigal Pharmaceuticals reports Q4 EPS ($2.57), consensus (88c)
Reports Q4 revenue $321.083M, consensus $312.74M. Bill Sibold, Chief Executive Officer of Madrigal, stated: “2025 marked a defining year for Madrigal. We solidified our position as the undisputed lead...
Madrigal Pharmaceuticals announces exclusive license pact with Suzho Ribo
Madrigal Pharmaceuticals (MDGL) announced an exclusive global license agreement with Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals for six preclinical small interfering RNA prog...
Madrigal Pharmaceuticals price target lowered to $570 from $595 at BofA
BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $570 from $595 and keeps a Neutral rating on the shares. Given the level of pre-announcements, upcoming Q4 earnings…
Madrigal Pharmaceuticals initiated with an Overweight at Barclays
Barclays initiated coverage of Madrigal Pharmaceuticals (MDGL) with an Overweight rating and $964 price target Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positi...
Madrigal Pharmaceuticals price target raised to $745 from $527 at Citizens
Citizens raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $745 from $527 and keeps an Outperform rating on the shares. Rezdiffra’s extended intellectual property coverage and multi...